Immunomodulating drugs

Application ( S )-(+)-2-Amino-3-methyl-1-butanol can be used to prepare: Imines and oxazolines by reacting with aldehydes and nitriles, respectively. Chiral oxazoline derived multidentate ligands containing cyclophosphazene moiety.

Application ( S )-(+)-2-Amino-3-methyl-1-butanol can be used to prepare: Imines and oxazolines by reacting with aldehydes and nitriles, respectively. Chiral oxazoline derived multidentate ligands containing cyclophosphazene moiety.

Reactant involved in the synthesis of biologically active molecules including: · Acyclonucleoside phosphonates structural analogs of adefovir · Labeled discodermolide for studying binding to tubulin · 10-Isocyano-4-cadinene used for antifouling

Reactant involved in the synthesis of biologically active molecules including: · Acyclonucleoside phosphonates structural analogs of adefovir · Labeled discodermolide for studying binding to tubulin · 10-Isocyano-4-cadinene used for antifouling

Reactant involved in the synthesis of biologically active molecules including: · Acyclonucleoside phosphonates structural analogs of adefovir · Labeled discodermolide for studying binding to tubulin · 10-Isocyano-4-cadinene used for antifouling

Product Describtion:(S)-(-)-Thalidomide is an optically active isomer of Thalidomide. Inhibits FGF-induced angiogenesis and replication of human immunodeficiency virus type 1.Product Application：Optically active isomer of Thalidomide, which inhibits

Product Describtion:(S)-(-)-Thalidomide is an optically active isomer of Thalidomide. Inhibits FGF-induced angiogenesis and replication of human immunodeficiency virus type 1.Product Application：Optically active isomer of Thalidomide, which inhibits

(S)-Ibrutinib is a highly selective irreversible Btk (Bruton′s tyrosine kinase) inhibitor.

(S)-Ibrutinib is a highly selective irreversible Btk (Bruton′s tyrosine kinase) inhibitor.

(S)-N-(2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)propionamide.

(S)-N-(2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)propionamide.

A methylsulfanylimidazole that inhibits p38 MAP kinase (IC₅₀ = 0.90 &microM in vitro) potently blocks the release of TNF-&alpha and IL-1&beta from human peripheral blood mononuclear cells (IC₅₀s = 0.